Urogen pharma ltd. (URGN)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16
REVENUES

18

1,128

8,158

17,530

COST OF REVENUES

-

1,803

600

28

GROSS (LOSS) PROFIT

18

-675

7,558

17,502

OPERATING EXPENSES:
RESEARCH AND DEVELOPMENT EXPENSES

49,297

36,934

18,697

10,287

GENERAL AND ADMINISTRATIVE EXPENSES

60,199

39,571

8,811

6,417

OPERATING LOSS

-109,478

-77,180

-19,950

798

INTEREST AND OTHER INCOME, NET

4,332

1,648

-31

-

FINANCE INCOME, NET

-

-

-

-2,739

LOSS BEFORE INCOME TAXES

-105,146

-75,532

-19,981

-1,941

INCOME TAX EXPENSE

-

125

19

-

NET LOSS

-105,146

-75,657

-20,000

-1,941

STATEMENTS OF COMPREHENSIVE LOSS
NET LOSS

-105,146

-75,657

-20,000

-

OTHER COMPREHENSIVE INCOME:
UNREALIZED GAIN ON MARKETABLE SECURITIES

276

-

-

-

COMPREHENSIVE LOSS

-104,870

-75,657

-20,000

-

NET LOSS PER ORDINARY SHARE BASIC AND DILUTED

-5.12

-4.80

-2.14

-1.91

WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER ORDINARY SHARE

20,528

15,754

9,716

2,305